ストックスクリーナーアプリを入手
12.34
4.31%
0.51
アフターアワーズ：
12.34
前日終値:
$11.83
開ける：
$11.73
24時間の取引高:
437.03K
Relative Volume:
2.51
時価総額：
$614.15M
収益：
-
当期純損益:
$-119.67M
株価収益率:
-8.7487
EPS:
-1.4105
ネットキャッシュフロー:
$-97.30M
1週間 パフォーマンス:
+3.70%
1か月 パフォーマンス:
-2.06%
6か月 パフォーマンス:
+5.38%
1年 パフォーマンス:
+62.37%
1日の値動き範囲:
$11.55
$12.50
1週間の範囲:
$11.19
$12.57
52週間の値動き範囲:
$7.29
$16.91
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
名前
Mineralys Therapeutics Inc
セクター
電話
(888) 378-6240
住所
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
12.34 | 614.15M | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-02 | 開始されました | Goldman | Buy |
| 2023-03-07 | 開始されました | BofA Securities | Buy |
| 2023-03-07 | 開始されました | Credit Suisse | Outperform |
| 2023-03-07 | 開始されました | Evercore ISI | Outperform |
| 2023-03-07 | 開始されました | Guggenheim | Buy |
| 2023-03-07 | 開始されました | Stifel | Buy |
| 2023-03-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Mineralys Therapeutics Inc (MLYS) 最新ニュース
Mineralys Therapeutics (NASDAQ:MLYS) Shares Up 3%Here's Why - MarketBeat
Franklin Resources Inc. Increases Stock Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat
Wellington Management Group LLP Invests $775,000 in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm! - The Eastern Progress Online
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc.MLYS - The Eastern Progress Online
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 3.8%Here's Why - MarketBeat
Polar Asset Management Partners Inc. Takes $490,000 Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat
(MLYS) Trading Report - Stock Traders Daily
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Holdings Raised by Caligan Partners LP - MarketBeat
(MLYS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Mineralys Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN
Mineralys Therapeutics to Participate in Goldman Sachs Healthcare Conference - MSN
Mineralys Therapeutics Set to Engage with Investors at Key Conferences - MSN
Mineralys Therapeutics Inc (MLYS) Quarterly 10-Q Report - Quartzy
What is Lifesci Capital's Forecast for MLYS FY2024 Earnings? - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for MLYS - MarketBeat
(MLYS) Trading Signals - Stock Traders Daily
Mineralys therapeutics CMO sells shares worth $75,398 By Investing.com - Investing.com Australia
MineralysTargeting Aldosterone To Combat Obesity-Driven Hypertension And Kidney Disease - RTTNews
Mineralys Therapeutics Announces Q3 2024 Results and Updates - Yahoo Finance
Mineralys Therapeutics' (MLYS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2024 Earnings Call Transcript - MSN
Mineralys Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mineralys Therapeutics reports Q3 EPS ($1.13), consensus (83c) - TipRanks
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
David Malcom Rodman Sells 25,482 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics' chief medical officer sells $383,065 in stock - Investing.com
Insights into Mineralys Therapeutics's Upcoming Earnings - Benzinga
Mineralys Therapeutics to Announce Third-Quarter 2024 Financial Results - MyChesCo
Mineralys Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Mineralys Therapeutics (MLYS) to Release Quarterly Earnings on Monday - MarketBeat
Mineralys Therapeutics (MLYS) to Present at Three Major Healthcare Conferences | MLYS Stock News - StockTitan
Mineralys Therapeutics to Announce Third Quarter 2024 - GlobeNewswire
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 - Marketscreener.com
Mineralys Therapeutics’ (MLYS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Objective long/short (MLYS) Report - Stock Traders Daily
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial - MSN
Mineralys Therapeutics (NASDAQ:MLYS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Mineralys Therapeutics : Corporate Overview October 2024 - Marketscreener.com
Mineralys Therapeutics Advances Lorundrostat Trial Progress - TipRanks
Mineralys Therapeutics Completes Enrollment Ahead of - GlobeNewswire
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension - The Manila Times
Mineralys Therapeutics Inc (MLYS) 財務データ
収益
当期純利益
現金流量
EPS
Mineralys Therapeutics Inc (MLYS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Rodman David Malcom | Chief Medical Officer |
Nov 11 '24 |
Option Exercise |
0.81 |
10,043 |
8,137 |
146,017 |
| Rodman David Malcom | Chief Medical Officer |
Nov 11 '24 |
Sale |
15.00 |
5,026 |
75,398 |
140,991 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):